Ervin Steve Woodle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9230753/publications.pdf

Version: 2024-02-01

194 papers 10,847 citations

28274 55 h-index 96 g-index

202 all docs $\begin{array}{c} 202 \\ \\ \text{docs citations} \end{array}$

times ranked

202

8420 citing authors

#	Article	IF	CITATIONS
1	One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) Trial. Kidney International Reports, 2022, 7, 241-250.	0.8	12
2	Urine Proteomics and Renal <scp>Singleâ€Cell</scp> Transcriptomics Implicate Interleukinâ€16 in Lupus Nephritis. Arthritis and Rheumatology, 2022, 74, 829-839.	5 . 6	38
3	Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. American Journal of Transplantation, 2021, 21, 475-483.	4.7	45
4	Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients. American Journal of Transplantation, 2021, 21, 1691-1698.	4.7	18
5	Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. American Journal of Transplantation, 2021, 21, 460-474.	4.7	67
6	Early Corticosteroid Cessation vs Long-term Corticosteroid Therapy in Kidney Transplant Recipients. JAMA Surgery, 2021, 156, 307.	4.3	16
7	SARS-CoV-2 Vaccination and Antibody Testing in Immunosuppressed Populations. Transplantation, 2021, Publish Ahead of Print, .	1.0	1
8	Plasma cell biology: Foundations for targeted therapeutic development in transplantation. Immunological Reviews, 2021, 303, 168-186.	6.0	3
9	Belatacept for Simultaneous Calcineurin Inhibitor and Chronic Corticosteroid Immunosuppression Avoidance. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1387-1397.	4.5	13
10	Seroprevalence of SARS-CoV-2 infection in Cincinnati Ohio USA from August to December 2020. PLoS ONE, 2021, 16, e0254667.	2. 5	4
11	SARS-CoV-2 Vaccination, Immune Responses, and Antibody Testing in Immunosuppressed Populations: Tip of the Iceberg. Transplantation, 2021, 105, 1911-1913.	1.0	5
12	Delayed Kinetics of IgG, but Not IgA, Antispike Antibodies in Transplant Recipients following SARS-CoV-2 Infection. Journal of the American Society of Nephrology: JASN, 2021, 32, 3221-3230.	6.1	14
13	Advanced Genomics-Based Approaches for Defining Allograft Rejection With Single Cell Resolution. Frontiers in Immunology, 2021, 12, 750754.	4.8	5
14	Incorporating Patients' Values and Preferences Into Decision Making About Transplantation of HCV-Naà ve Recipients With Kidneys From HCV-Viremic Donors: A Feasibility Study. MDM Policy and Practice, 2021, 6, 238146832110565.	0.9	1
15	Proteasomal adaptations underlying carfilzomib-resistance in human bone marrow plasma cells. American Journal of Transplantation, 2020, 20, 399-410.	4.7	18
16	Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: A prospective, randomized multicenter trial. American Journal of Transplantation, 2020, 20, 1039-1055.	4.7	39
17	A prospective, iterative, adaptive trial of carfilzomib-based desensitization. American Journal of Transplantation, 2020, 20, 411-421.	4.7	47
18	Long-term outcomes in patients with obesity and renal disease after sleeve gastrectomy. American Journal of Transplantation, 2020, 20, 422-429.	4.7	54

#	Article	IF	Citations
19	Reducing Donor-specific Antibody During Acute Rejection Diminishes Long-term Renal Allograft Loss: Comparison of Early and Late Rejection. Transplantation, 2020, 104, 2403-2414.	1.0	6
20	Multicenter Study to Transplant Hepatitis C–Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. Journal of the American Society of Nephrology: JASN, 2020, 31, 2678-2687.	6.1	55
21	Plasma cell targeting to prevent antibody-mediated rejection. American Journal of Transplantation, 2020, 20, 33-41.	4.7	16
22	mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28â^ Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection. Transplantation, 2020, 104, 1058-1069.	1.0	13
23	Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients. American Journal of Kidney Diseases, 2020, 75, 857-867.	1.9	26
24	Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant. American Journal of Transplantation, 2019, 19, 3035-3045.	4.7	44
25	High-Dimensional Renal Profiling: Towards a Better Understanding of Renal Transplant Immune Suppression. Current Transplantation Reports, 2019, 6, 60-68.	2.0	O
26	Use of HCV Ab+/NATâ $^{\circ}$ donors in HCV na \tilde{A} -ve renal transplant recipients to expand the kidney donor pool. Clinical Transplantation, 2019, 33, e13598.	1.6	21
27	The immune cell landscape in kidneys of patients with lupus nephritis. Nature Immunology, 2019, 20, 902-914.	14.5	501
28	Rabbit anti-thymocyte globulin for the prevention of acute rejection in kidney transplantation. American Journal of Transplantation, 2019, 19, 2252-2261.	4.7	24
29	Clinical Implications of Donor Warm and Cold Ischemia Time in Donor After Circulatory Death Liver Transplantation. Liver Transplantation, 2019, 25, 1342-1352.	2.4	49
30	Impact of Induction Therapy on Circulating T Follicular Helper Cells and Subsequent Donor-Specific Antibody Formation After Kidney Transplant. Kidney International Reports, 2019, 4, 455-469.	0.8	31
31	Bariatric surgery prior to living donor nephrectomy: a solution to expand the living donor kidney pool – a retrospective study. Transplant International, 2019, 32, 702-709.	1.6	7
32	AB0167â€SINGLE CELL RNA EXPRESSION IN LUPUS NEPHRITIS COMPARING AFRICAN-AMERICAN AND CAUCAS PATIENTS IDENTIFIES DIFFERENTIAL EXPRESSION OF TYPE I INTERFERON PATHWAY., 2019,,.	JIAN	0
33	Telemedicine Based Remote Home Monitoring After Liver Transplantation. Annals of Surgery, 2019, 270, 564-572.	4.2	59
34	Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values. American Journal of Transplantation, 2019, 19, 1410-1420.	4.7	79
35	Treatment of large renal allograft arterial pseudoaneurysm with in situ cold perfusion, ex vivo vascular reconstruction and reimplantation. Journal of Nephropathology, 2019, 8, 10-10.	0.2	0
36	A phase Ib, open-label, single arm study to assess the safety, pharmacokinetics, and impact on humoral sensitization of SANGUINATE infusion in patients with end-stage renal disease. Clinical Transplantation, 2018, 32, e13155.	1.6	15

#	Article	IF	Citations
37	Transplanting Hepatitis C Virus–Infected or Uninfected Kidneys Into Hepatitis C Virus–Infected Recipients. Annals of Internal Medicine, 2018, 169, 898.	3.9	0
38	Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis. PLoS Medicine, 2018, 15, e1002572.	8.4	76
39	Transplanting Hepatitis C Virus–Infected Versus Uninfected Kidneys Into Hepatitis C Virus–Infected Recipients. Annals of Internal Medicine, 2018, 169, 214.	3.9	23
40	Addressing the challenges of sleeve gastrectomy in end-stage renal disease: Analysis of 100 consecutive renal failure patients. Surgery, 2017, 162, 358-365.	1.9	13
41	Targeting Plasma Cells with Proteasome Inhibitors: Principles from Primates. Journal of the American Society of Nephrology: JASN, 2017, 28, 1951-1953.	6.1	14
42	Pharmacokinetic and pharmacogenetic analysis of immunosuppressive agents after laparoscopic sleeve gastrectomy. Clinical Transplantation, 2017, 31, e12975.	1.6	23
43	lgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. New England Journal of Medicine, 2017, 377, 1692-1694.	27.0	14
44	Contrast-Induced Nephropathy in Renal Transplant Recipients: A Single Center Experience. Frontiers in Medicine, 2017, 4, 64.	2.6	8
45	Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial. PLoS Medicine, 2017, 14, e1002428.	8.4	29
46	Absence of the Effect of Pretransplant Body Mass Index on Post Kidney Transplant Outcomes. Progress in Transplantation, 2016, 26, 183-190.	0.7	10
47	Case Report: Successful Living Donor Kidney Transplantation in a Highly Human Leukocyte Antigen-Sensitized Recipient With a Positive Cytotoxic Crossmatch Using Bortezomib-Based Desensitization Without Intravenous Immunoglobulin. Transplantation Proceedings, 2015, 47, 2254-2257.	0.6	3
48	Case Report: Hemolytic Anemia Following Deceased Donor Renal Transplantation Associated With Tranexamic Acid Administration for Disseminated Intravascular Coagulation. Transplantation Proceedings, 2015, 47, 2239-2242.	0.6	4
49	Effect of pretransplant diabetes on shortâ€ŧerm outcomes after liver transplantation: A National cohort study. Liver International, 2015, 35, 1902-1909.	3.9	44
50	A Banff Component Scoring-based Histologic Assessment of Bortezomib-based Antibody-mediated Rejection Therapy. Transplantation, 2015, 99, 1691-1699.	1.0	10
51	Acute Rejection Clinically Defined Phenotypes Correlate With Long-term Renal Allograft Survival. Transplantation, 2015, 99, 2167-2173.	1.0	26
52	Independent effect of black recipient race on short-term outcomes after liver transplantation. Surgery, 2015, 157, 774-784.	1.9	23
53	Hospital Resource Use with Donation after Cardiac Death Allografts in Liver Transplantation: A Matched Controlled Analysis from 2007 to 2011. Journal of the American College of Surgeons, 2015, 220, 951-958.	0.5	20
54	Living Donor Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1670-1677.	4.5	53

#	Article	IF	CITATIONS
55	Impact of recipient morbid obesity on outcomes after liver transplantation. Transplant International, 2015, 28, 148-155.	1.6	66
56	Prospective Iterative Trial of Proteasome Inhibitor-Based Desensitization. American Journal of Transplantation, 2015, 15, 101-118.	4.7	127
57	Review of Bortezomib Treatment of Antibody-Mediated Rejection in Renal Transplantation. Antioxidants and Redox Signaling, 2014, 21, 2401-2418.	5.4	45
58	Comparing living donor and deceased donor liver transplantation: A matched national analysis from 2007 to 2012. Liver Transplantation, 2014, 20, 1347-1355.	2.4	56
59	Is liver transplantation safe and effective in elderly (≥70 years) recipients? A case-controlled analysis. Hpb, 2014, 16, 1088-1094.	0.3	62
60	Desensitization in kidney transplantation: review and future perspectives. Clinical Transplantation, 2014, 28, 494-507.	1.6	63
61	Increasing prevalence of nonalcoholic steatohepatitis as an indication for liver transplantation. Surgery, 2014, 156, 1049-1056.	1.9	21
62	Hospital utilization and consequences of readmissions after liver transplantation. Surgery, 2014, 156, 871-879.	1.9	38
63	Bortezomib Is a Successful Therapeutic Agent for Refractory Autoimmune Cytopenias in Children: A Single Center Experience. Biology of Blood and Marrow Transplantation, 2014, 20, S174.	2.0	0
64	Neighborhood Level Effects of Socioeconomic Status on Liver Transplant Selection and Recipient Survival. Clinical Gastroenterology and Hepatology, 2014, 12, 1934-1941.	4.4	64
65	Bortezomib-Based Antibody-Mediated Rejection Therapy and Simultaneous Conversion to Belatacept. Transplantation, 2014, 97, e30-e32.	1.0	1
66	Randomized Controlled Pilot Study of B Cell–Targeted Induction Therapy in HLA Sensitized Kidney Transplant Recipients. American Journal of Transplantation, 2013, 13, 3142-3154.	4.7	35
67	Management of Antibody-Mediated Rejection in Transplantation. Surgical Clinics of North America, 2013, 93, 1451-1466.	1.5	13
68	Acute Rejection Characteristics From a Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Early Corticosteroid Withdrawal. Transplantation, 2013, 95, 573-579.	1.0	12
69	Proteasome inhibitor-based therapy for antibody-mediated rejection. Kidney International, 2012, 81, 1067-1074.	5. 2	92
70	Prospective Evaluation of the Toxicity Profile of Proteasome Inhibitor–Based Therapy in Renal Transplant Candidates and Recipients. Transplantation, 2012, 94, 352-361.	1.0	37
71	Rapid Reduction in Donor-Specific Anti-Human Leukocyte Antigen Antibodies and Reversal of Antibody-Mediated Rejection With Bortezomib in Pediatric Heart Transplant Patients. Transplantation, 2012, 93, 319-324.	1.0	90
72	4-OR. Human Immunology, 2012, 73, 4.	2.4	0

#	Article	IF	CITATIONS
73	Targeting the Ubiquitin+Proteasome System in Solid Tumors. Seminars in Hematology, 2012, 49, 277-283.	3.4	31
74	Proteasome Inhibition for Antibody-Mediated Allograft Rejection. Seminars in Hematology, 2012, 49, 263-269.	3.4	20
75	Proteasome inhibitor treatment of antibody-mediated allograft rejection. Current Opinion in Organ Transplantation, 2011, 16, 434-438.	1.6	37
76	Early and Late Acute Antibody-Mediated Rejection Differ Immunologically and in Response to Proteasome Inhibition. Transplantation, 2011, 91, 1218-1226.	1.0	139
77	Association Between Donor-Specific Antibodies and Acute Rejection and Resolution in Small Bowel and Multivisceral Transplantation. Transplantation, 2011, 92, 709-715.	1.0	68
78	FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study. Nephrology Dialysis Transplantation, 2011, 26, 3802-3805.	0.7	44
79	Steroid minimization for sirolimusâ€treated renal transplant recipients. Clinical Transplantation, 2011, 25, 457-467.	1.6	6
80	YSPSL (rPSGLâ€Ig) for improvement of early renal allograft function: a doubleâ€blind, placeboâ€controlled, multiâ€center Phase IIa study ^{1,2,3} . Clinical Transplantation, 2011, 25, 523-533.	1.6	49
81	Proteasome inhibitor therapy for antibodyâ€mediated rejection. Pediatric Transplantation, 2011, 15, 548-556.	1.0	32
82	Regulatory Approval for New Antihumoral Therapies: Addressing the Barriers. American Journal of Transplantation, 2011, 11, 880-881.	4.7	2
83	Of Mice and Men: Terminal Complement Inhibition With Anti-C5 Monoclonal Antibodies. American Journal of Transplantation, 2011, 11, 2277-2278.	4.7	5
84	Clinical and investigational use of proteasome inhibitors for transplant rejection. Expert Opinion on Investigational Drugs, 2011, 20, 1535-1542.	4.1	12
85	Alemtuzumab Induction in Renal Transplantation. New England Journal of Medicine, 2011, 364, 1909-1919.	27.0	360
86	Malignant Melanoma in Solid Transplant Recipients. Archives of Dermatology, 2011, 147, 790.	1.4	89
87	Proteasome Inhibitor-Based Primary Therapy for Antibody-Mediated Renal Allograft Rejection. Transplantation, 2010, 89, 277-284.	1.0	166
88	Clinical Review of Nonalcoholic Steatohepatitis in Liver Surgery and Transplantation. Journal of the American College of Surgeons, 2010, 210, 515-526.	0.5	34
89	Rare subtypes of BK virus are viable and frequently detected in renal transplant recipients with BK virus-associated nephropathy. Virology, 2010, 404, 312-318.	2.4	28
90	Ethical Considerations for Participation of Nondirected Living Donors in Kidney Exchange Programs. American Journal of Transplantation, 2010, 10, 1460-1467.	4.7	50

#	Article	IF	CITATIONS
91	A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with Thymoglobulin [®] in livingâ€donor kidney transplantation. Clinical Transplantation, 2010, 24, 73-83.	1.6	69
92	Assessment of Efficacy and Safety of FK778 in Comparison With Standard Care in Renal Transplant Recipients With Untreated BK Nephropathy. Transplantation, 2010, 90, 891-897.	1.0	45
93	Reducing De Novo Donor-Specific Antibody Levels during Acute Rejection Diminishes Renal Allograft Loss. American Journal of Transplantation, 2009, 9, 1063-1071.	4.7	199
94	Proteasome inhibition for antibody-mediated rejection. Current Opinion in Organ Transplantation, 2009, 14, 662-666.	1.6	86
95	De Novo Cancers Arising in Organ Transplant Recipients are Associated With Adverse Outcomes Compared With the General Population. Transplantation, 2009, 87, 1347-1359.	1.0	173
96	A Prospective Trial of a Steroid-Free/Calcineurin Inhibitor Minimization Regimen in Human Leukocyte Antigen (HLA)-Identical Live Donor Renal Transplantation. Transplantation, 2009, 87, 408-414.	1.0	14
97	BKV and JCV large T antigen-specific CD8+ T cell response in HLA A*0201+ kidney transplant recipients with polyomavirus nephropathy and patients with progressive multifocal leukoencephalopathy. Journal of Clinical Virology, 2008, 42, 198-202.	3.1	37
98	A Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial Comparing Early (7) Tj ETQq0 0 C Surgery, 2008, 248, 564-577.	O rgBT /Ov 4.2	erlock 10 Tf 5 420
99	Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection. Transplantation, 2008, 86, 1754-1761.	1.0	362
100	Risk Assessment of Immunosuppressive Therapy in Facial Transplantation. Plastic and Reconstructive Surgery, 2007, 120, 657-668.	1.4	42
101	Monitoring of Inosine Monophosphate Dehydrogenase Activity as a Biomarker for Mycophenolic Acid Effect: Potential Clinical Implications. Therapeutic Drug Monitoring, 2007, 29, 141-149.	2.0	39
102	Temporary silastic mesh closure for adult liver transplantation: A safe alternative for the difficult abdomen. Liver Transplantation, 2007, 13, 258-265.	2.4	38
103	Reply: Temporary abdominal coverage for adult liver transplantation. Liver Transplantation, 2007, 13, 1351-1352.	2.4	0
104	Corticosteroid elimination: the Cincinnati experience. Clinical Transplants, 2007, , 51-60.	0.2	2
105	Malignancy in pediatric transplant recipients. Seminars in Pediatric Surgery, 2006, 15, 179-187.	1.1	55
106	How can donors with a previous malignancy be evaluated?. Journal of Hepatology, 2006, 45, 503-507.	3.7	21
107	Simultaneous corticosteroid avoidance and calcineurin inhibitor minimization in renal transplantation. Transplant International, 2006, 19, 295-302.	1.6	24
108	Liver transplantation for primary and metastatic hepatic malignancy: a single center experience. Surgery, 2006, 139, 535-541.	1.9	1

#	Article	IF	CITATIONS
109	Interplay of Cellular and Humoral Immune Responses against BK Virus in Kidney Transplant Recipients with Polyomavirus Nephropathy. Journal of Virology, 2006, 80, 3495-3505.	3.4	129
110	Malignancy after Transplantation. Transplantation, 2005, 80, S254-S264.	1.0	482
111	The Influence of Immunomodulatory Diets on Transplant Success and Complications. Transplantation, 2005, 79, 460-465.	1.0	25
112	United Network for Organ Sharing Publication on Scientific Registry of Transplant Recipients Central Nervous System Donor Cancer Transmission Data. Transplantation, 2005, 79, 623.	1.0	6
113	Laparoscopic donor nephrectomy vs. open live donor nephrectomy: a quality of life and functional study. Clinical Transplantation, 2005, 19, 102-109.	1.6	70
114	Consequences of vancomycin-resistant Enterococcus in liver transplant recipients: a matched control study. Clinical Transplantation, 2005, 19, 050824032258001.	1.6	56
115	Laparoscopic liver resection. Journal of the American College of Surgeons, 2005, 200, 472-480.	0.5	82
116	A Multicenter Pilot Study of Early (4-Day) Steroid Cessation in Renal Transplant Recipients Under Simulect, Tacrolimus and Sirolimus. American Journal of Transplantation, 2005, 5, 157-166.	4.7	86
117	African-American Renal Transplant Recipients Benefit from Early Corticosteroid Withdrawal Under Modern Immunosuppression. American Journal of Transplantation, 2005, 5, 356-365.	4.7	32
118	Analysis of Factors that Influence Survival with Post-Transplant Lymphoproliferative Disorder in Renal Transplant Recipients: The Israel Penn International Transplant Tumor Registry Experience. American Journal of Transplantation, 2005, 5, 775-780.	4.7	95
119	A Comparison of Tacrolimus and Cyclosporine in Liver Transplantation: Effects on Renal Function and Cardiovascular Risk Status. American Journal of Transplantation, 2005, 5, 1111-1119.	4.7	83
120	Multivariate Analysis of Risk Factors for Acute Rejection in Early Corticosteroid Cessation Regimens Under Modern Immunosuppression. American Journal of Transplantation, 2005, 5, 2740-2744.	4.7	62
121	Skin Cancer Following Transplantation: The Israel Penn International Transplant Tumor Registry Experience. Transplantation Proceedings, 2005, 37, 962-963.	0.6	56
122	Early Steroid Withdrawal Does Not Increase Risk for Recurrent Focal Segmental Glomerulosclerosis. Transplantation Proceedings, 2005, 37, 817-818.	0.6	13
123	Pilot Study of Early Corticosteroid Elimination After Pancreas Transplantation. Transplantation Proceedings, 2005, 37, 1287-1288.	0.6	7
124	Early Corticosteroid Withdrawal Under Modern Immunosuppression in Renal Transplantation: Multivariate Analysis of Risk Factors for Acute Rejection. Transplantation Proceedings, 2005, 37, 798-799.	0.6	8
125	A Prospective, Randomized, Multicenter, Double-Blind Study of Early Corticosteroid Cessation Versus Long-Term Maintenance of Corticosteroid Therapy With Tacrolimus and Mycophenolate Mofetil in Primary Renal Transplant Recipients: One Year Report. Transplantation Proceedings, 2005, 37, 804-808.	0.6	30
126	Donor Kidneys With Small Renal Cell Cancers: Can They Be Transplanted?. Transplantation Proceedings, 2005, 37, 581-582.	0.6	63

#	Article	IF	Citations
127	Chemotherapy for Posttransplant Lymphoproliferative Disorder: The Israel Penn International Transplant Tumor Registry Experience. Transplantation Proceedings, 2005, 37, 956-957.	0.6	54
128	Central Nervous System Tumors in Donors: Misdiagnosis Carries a High Morbidity and Mortality. Transplantation Proceedings, 2005, 37, 583-584.	0.6	44
129	Laparoscopic Right Living Donor Nephrectomy. Transplantation Proceedings, 2005, 37, 631-632.	0.6	26
130	Prostate Cancer Prior to Solid Organ Transplantation: The Israel Penn International Transplant Tumor Registry Experience. Transplantation Proceedings, 2005, 37, 958-959.	0.6	41
131	Laparoscopic Living Donor Nephrectomy for Kidneys With Multiple Arteries. Transplantation Proceedings, 2005, 37, 629-630.	0.6	29
132	Influence of Educational Programs on Perceived Barriers Toward Living Donor Kidney Exchange Programs. Transplantation Proceedings, 2005, 37, 602-604.	0.6	9
133	Histocompatibility Testing Predicts Acute Rejection Risk in Early Corticosteroid Withdrawal Regimens. Transplantation Proceedings, 2005, 37, 809-811.	0.6	8
134	Transplant-Related Malignancies. , 2005, , 1149-1164.		4
135	Posttransplant Malignancy. Progress in Transplantation, 2004, 14, 193-200.	0.7	21
136	An initial experience and evolution of laparoscopic hepatic resectional surgery. Surgery, 2004, 136, 804-811.	1.9	131
137	Characteristics and Survival Patterns of Solid Organ Transplant Patients Developing De Novo Colon and Rectal Cancer. Diseases of the Colon and Rectum, 2004, 47, 1898-1903.	1.3	57
138	Syndromic incidence of ovarian cancer after liver transplantation: Is breast cancer an antecedent risk?. Liver Transplantation, 2004, 10, 156-157.	2.4	4
139	West Nile virus encephalitis in organ transplant recipients: another high-risk group for meningoencephalitis and death1. Transplantation, 2004, 77, 466-469.	1.0	73
140	Experience with 274 Cardiac Transplant Recipients with Posttransplant Lymphoproliferative Disorder: A Report from the Israel Penn International Transplant Tumor Registry. Transplantation, 2004, 78, 1676-1682.	1.0	58
141	Recurrence Risk After Organ Transplantation in Patients with a History of Hodgkin Disease or Non-Hodgkin Lymphoma. Transplantation, 2004, 78, 972-977.	1.0	18
142	Right donor nephrectomy: A comparison of hand-assisted transperitoneal and retroperitoneal laparoscopic approaches. Transplantation, 2004, 77, 521-525.	1.0	64
143	Gastric Bypass in Morbidly Obese Patients with Chronic Renal Failure and Kidney Transplant. Transplantation, 2004, 78, 469-474.	1.0	87
144	Polyomavirus Nephropathy in Kidney Transplantation. Progress in Transplantation, 2004, 14, 130-142.	0.7	19

#	Article	IF	CITATIONS
145	Polyomavirus nephropathy in kidney transplantation. Progress in Transplantation, 2004, 14, 130-142.	0.7	21
146	Posttransplant malignancy. Progress in Transplantation, 2004, 14, 193-200.	0.7	20
147	A history of living donor transplantation. Transplantation Proceedings, 2003, 35, 901-902.	0.6	1
148	Maximizing renal artery length in right laparoscopic donor nephrectomy by retrocaval exposure of the aortorenal junction. Transplantation, 2003, 75, 83-85.	1.0	22
149	MALTOMA: A helicobacter pylori-associated malignancy in transplant patients. Transplantation, 2003, 75, 225-228.	1.0	29
150	Donors with central nervous system malignancies: are they truly safe?. Transplantation, 2003, 76, 340-343.	1.0	92
151	Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on cd3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation, 2002, 73, 1514-1518.	1.0	106
152	Successful retransplantation after renal allograft loss to polyoma virus interstitial nephritis. Transplantation, 2002, 73, 1166-1169.	1.0	50
153	Corticosteroid elimination in renal transplantation: pro. Transplantation Proceedings, 2002, 34, 1693.	0.6	5
154	Incidental diagnosis of gastric cancer in transplant recipients improves patient survival. Surgery, 2002, 132, 754-760.	1.9	12
155	Hand-Assisted Laparoscopic Living-Donor Nephrectomy as an Alternative to Traditional Laparoscopic Living-Donor Nephrectomy. American Journal of Transplantation, 2002, 2, 983-988.	4.7	58
156	Surgical techniques in right laparoscopic donor nephrectomy 11No competing interests declared Journal of the American College of Surgeons, 2002, 195, 131-137.	0.5	41
157	Kidney Transplantation: Graft Monitoring and Immunosuppression. World Journal of Surgery, 2002, 26, 185-193.	1.6	8
158	The Role of Immunosuppression in Lymphoma. Recent Results in Cancer Research, 2002, 159, 55-66.	1.8	20
159	Are Concerns Over Right Laparoscopic Donor Nephrectomy Unwarranted?. Annals of Surgery, 2001, 233, 645-651.	4.2	110
160	PRIMUM NON NOCERE: AVOIDING HARM TO VULNERABLE WAIT LIST CANDIDATES IN AN INDIRECT KIDNEY EXCHANGE. Transplantation, 2001, 72, 648-654.	1.0	84
161	Laparoscopic Live Donor Nephrectomy: Rationale, Techniques, and Implications. Seminars in Dialysis, 2001, 14, 365-372.	1.3	9
162	DIETARY SUPPLEMENTATION WITH L-ARGININE AND CANOLA OIL REDUCES REJECTION EPISODES, RENAL BIOPSIES, REHOSPITALIZATION AND BLOOD PRESSURE FOLLOWING RENAL TRANSPLANTATION Transplantation, 2000, 69, S362.	1.0	0

#	Article	IF	CITATIONS
163	EARLY CORTICOSTEROID CESSATION AT ONE WEEK FOLLOWING KIDNEY TRANSPLANT UNDER TACROLIMUS AND MYCOPHENOLATE MOFETIL (MMF) IMMUNOSUPPRESION, THREE-YEAR FOLLOW-UP Transplantation, 2000, 69, S134.	1.0	18
164	Primary Living-Donor Liver Transplantation at the University of Chicago. Annals of Surgery, 2000, 232, 104-111.	4.2	122
165	Coadministration of Tacrolimus and Mycophenolate Mofetil in Stable Kidney Transplant Patients: Pharmacokinetics and Tolerability. Journal of Clinical Pharmacology, 2000, 40, 527-532.	2.0	34
166	PROGRAMMED CELL DEATH SIGNALING VIA CELL-SURFACE EXPRESSION OF A SINGLE-CHAIN ANTIBODY TRANSGENE. Transplantation, 2000, 69, 1209-1217.	1.0	4
167	ETHICAL ISSUES IN INCREASING LIVING KIDNEY DONATIONS BY EXPANDING KIDNEY PAIRED EXCHANGE PROGRAMS. Transplantation, 2000, 69, 1539-1543.	1.0	89
168	Corticosteroid withdrawal in renal transplantation. Transplantation Proceedings, 1999, 31, 247-248.	0.6	11
169	AFRICAN-AMERICAN PATIENTS WITH RENAL FAILURE SECONDARY TO DIABETES SHOULD BE REFERRED FOR COMBINED KIDNEY-PANCREAS TRANSPLANT. Transplantation, 1999, 67, S567.	1.0	1
170	PHASE I TRIAL OF A HUMANIZED, Fc RECEPTOR NONBINDING OKT3 ANTIBODY, huOKT3??1 (Ala-Ala) IN THE TREATMENT OF ACUTE RENAL ALLOGRAFT REJECTION. Transplantation, 1999, 68, 608-616.	1.0	170
171	EPSTEIN-BARR VIRUS-INDUCED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS. Transplantation, 1999, 68, 1517-1525.	1.0	489
172	The Relationship of Untreated Borderline Infiltrates by the Banff Criteria to Acute Rejection in Renal Allograft Biopsies. Journal of the American Society of Nephrology: JASN, 1999, 10, 1806-1814.	6.1	91
173	Complications in 100 Living-Liver Donors. Annals of Surgery, 1998, 228, 214-219.	4.2	176
174	INCIDENCE AND OUTCOME OF INFECTION BY VANCOMYCIN-RESISTANTENTEROCOCCUS FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATION. Transplantation, 1998, 65, 439-442.	1.0	88
175	PAIRED EXCHANGES SHOULD BE PART OF THE SOLUTION TO ABO INCOMPATIBILITY IN LIVING DONOR KIDNEY TRANSPLANTATION. Transplantation, 1998, 66, 406-407.	1.0	19
176	LIVER TRANSPLANTATION IN THE FIRST THREE MONTHS OF LIFE. Transplantation, 1998, 66, 606-609.	1.0	67
177	PROGRAMMED CELL DEATH. Transplantation, 1998, 66, 681-691.	1.0	56
178	Ethics of a Paired-Kidney-Exchange Program. New England Journal of Medicine, 1997, 336, 1752-1755.	27.0	185
179	CLASS I MHC MEDIATES PROGRAMMED CELL DEATH IN HUMAN LYMPHOID CELLS1. Transplantation, 1997, 64, 140-146.	1.0	12
180	IN VIVO ADMINISTRATION OF ANTI-MURINE CD3 MONOCLONAL ANTIBODY INDUCES SELECTIVE, LONG-TERM ANERGY IN CD8+ T CELLS. Transplantation, 1996, 61, 798-803.	1.0	22

#	Article	IF	CITATIONS
181	TACROLIMUS FOR PRIMARY TREATMENT OF STEROID-RESISTANT HEPATIC ALLOGRAFT REJECTION. Transplantation, 1996, 61, 1365-1369.	1.0	33
182	POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN PEDIATRIC LIVER TRANSPLANTATION. Transplantation, 1996, 62, 370-375.	1.0	272
183	LONG-TERM OUTCOME OF KIDNEY-PANCREAS TRANSPLANT RECIPIENTS WITH GOOD GRAFT FUNCTION AT ONE YEAR. Transplantation, 1996, 62, 451-456.	1.0	50
184	A MULTICENTER TRIAL OF FK506 (TACROLIMUS) THERAPY IN REFRACTORY ACUTE RENAL ALLOGRAFT REJECTION. Transplantation, 1996, 62, 594-599.	1.0	134
185	PORTAL VEIN THROMBOSIS AND STENOSIS IN PEDIATRIC LIVER TRANSPLANTATION 1. Transplantation, 1996, 62, 748-754.	1.0	150
186	TACROLIMUS THERAPY FOR REFRACTORY ACUTE RENAL ALLOGRAFT REJECTION. Transplantation, 1996, 62, 906-910.	1.0	35
187	USE OF POLYTETRAFLUOROETHYLENE PATCH FOR TEMPORARY WOUND CLOSURE AFTER PEDIATRIC LIVER TRANSPLANTATION. Transplantation, 1996, 62, 1034-1036.	1.0	36
188	COMPARISON OF PANCREAS TRANSPLANTATION WITH PORTAL VENOUS AND ENTERIC EXOCRINE DRAINAGE TO THE STANDARD TECHNIQUE UTILIZING BLADDER DRAINAGE OF EXOCRINE SECRETIONS. Transplantation, 1996, 62, 1353-1356.	1.0	81
189	OKT3 F(ABʾ)2 FRAGMENTS—RETENTION OF THE IMMUNOSUPPRESSIVE PROPERTIES OF WHOLE ANTIBODY WITH MARKED REDUCTION IN T CELL ACTIVATION AND LYMPHOKINE RELEASE. Transplantation, 1991, 52, 354-360.	1.0	34
190	OKT3 THERAPY FOR HEPATIC ALLOGRAFT REJECTION. Transplantation, 1991, 51, 1207-1212.	1.0	23
191	ANTI-CD3 MONOCLONAL ANTIBODY THERAPY. Transplantation, 1991, 52, 361-368.	1.0	20
192	ACTIVATION OF HUMAN T CELLS IN VIVO FOLLOWING TREATMENT OF TRANSPLANT RECIPIENTS WITH OKT3. Transplantation, 1990, 50, 608-612.	1.0	37
193	Hepatic perfusion abnormalities after liver transplantation. CardioVascular and Interventional Radiology, 1985, 8, 169-173.	2.0	O
194	Orthotopic Liver Transplantation in a Patient With Amanita Poisoning. JAMA - Journal of the American Medical Association, 1985, 253, 69.	7.4	42